Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Efrat Luttwak, Moshe E. Gatt, Eyal Lebel, Noa Lavi, Tamar Tadmor, Kreiniz Natalia, Noam Benyamini, Netanel Horowitz, Mika Geva, Celia Suriu, Irit Avivi, Svetlana Trestman, Moshe Mittelman, Ory Rouvio, Yael C. Cohen

Research output: Contribution to journalArticlepeer-review

Abstract

In a real-life multisite study, bortezomib (BTZ) maintenance therapy administered after a BTZ-based induction, with or without autologous transplantation, was safe, well tolerated, and effective in newly diagnosed myeloma patients. Progression-free survival (PFS) was 45 months, similar to that reported with lenalidomide maintenance therapy. Adverse cytogenetics was associated with worse PFS among patients treated with BTZ induction followed by maintenance therapy, but not in those who additionally underwent transplantation.

Original languageEnglish
Pages (from-to)e850-e857
JournalClinical Lymphoma, Myeloma and Leukemia
Volume20
Issue number11
DOIs
StatePublished - Nov 2020

Keywords

  • Bortezomib
  • Continuous therapy
  • Maintenance therapy
  • Multiple myeloma
  • Real-life experience

Fingerprint

Dive into the research topics of 'Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study'. Together they form a unique fingerprint.

Cite this